Halobet 20gm

Ointment

Pack Size : 1 Tube x 1 Packate

Generics : Halobetasol Propionate 0.05% Topical

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 130.00

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - Halobet 20gm

Description

Generic Name

Halobetasol Propionate 0.05% Topical

Precaution

Systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitaryadrenal (HPA) axis suppression, manifestations of cushing\'s syndrome, hyperglycemia, and glucosuria. Patients receiving large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Lactation: excretion of topical corticosteroids in breast milk is unknown; use with caution

Indication

Psoriasis, Eczema, Corticosteroid-responsive dermatoses

Contra Indication

Halobetasol Propionate Cream/Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Dose

N/A

Side Effect

Skin atrophy,Striae,Acneform lesions,Intracranial hypertension,Allergic contact dermatitis,Pruritus,Pustulation,Perioral dermatitis,Urticaria,Hypertrichosis,Leukoderma,Pigmentation changes,HPA suppression (with higher potency used >2 wk)

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation.

Interaction

N/A

Pregnancy Category Note

Pregnancy Data are unavailable for use in pregnant women to inform any drug associated risks for birth defects or miscarriage Animal studies Systemic administration during organogenesis to pregnant rats at 13-33 times the human topical dose and to pregnant rabbits at 3 times the human topical dose resulted in teratogenic and embryotoxic effects Lactation Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects in infant Unknown whether topical corticosteroids result in sufficient systemic absorption to produce detectable quantities in human milk Advise breastfeeding women not to apply halobetasol directly to the nipple and areola to avoid direct infant exposure

Adult Dose

Inflammatory, Pruritic & Steroid-Responsive Dermatoses Apply topically to affected area(s) BID Not to exceed 50 g/week; do not use longer than 2 consecutive weeks

Child Dose

Inflammatory, Pruritic & Steroid-Responsive Dermatoses <12 years: Safety and efficacy not established >12 years: Apply topically to affected area(s) BID Not to exceed 50 g/wk; do not use longer than 2 wk

Renal Dose

N/A

Administration

A thin layer should be applied to the affected skin once or twice daily and rub in gently and completely.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.